PIVOTAL
Disease site: Urological
Treatment Modality: Radiotherapy
Status: Open to recruitment
PIVOTAL is a phase II trial randomising between prostate and prostate + pelvic Intensity Modulated Radiotherapy (IMRT) in patients with locally advanced prostate cancer.
The primary objective is to evaluate the acute side effects of prostate + pelvic IMRT in a multi-centre setting. Should the level of side effects fall within a predefined acceptable range, the intention is to progress to a phase III trial investigating treatment efficacy.
The target number of participants is 110 over 2 years of recruitment.
Chief Investigator: | Professor David Dearnaley |
Sponsor: | The Institute of Cancer Research |
Source of funding: | Cancer Research UK |
ISRCTN: | tba |
In the Clinical Trials Section
